Results 81 to 90 of about 99,201 (311)

Management of Hematologic Malignancies

, 2010
Hematologic malignancies were the first human cancers to be studied in depth at the molecular level, and recent years have seen important advances in treatment.

core   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance

Nature Communications, 2021
miR-126 is highly expressed in inv(16) Acute myeloid leukemia (AML) but its role is unclear. Here, the authors show that the aberrant expression of miR-126 in inv(16) AML is directly due to the CBFB-MYH11 fusion gene and that it can promote AML ...
Lianjun Zhang, Le Xuan Truong Nguyen, Ying-Chieh Chen, Dijiong Wu, Guerry J. Cook, Dinh Hoa Hoang, Casey J. Brewer, Xin He, Haojie Dong, Shu Li, Man Li, Dandan Zhao, Jing Qi, Wei-Kai Hua, Qi Cai, Emily Carnahan, Wei Chen, Xiwei Wu, Piotr Swiderski, Russell C. Rockne, Marcin Kortylewski, Ling Li, Bin Zhang, Guido Marcucci, Ya-Huei Kuo   +24 more
doaj   +1 more source

Neoantigens in Hematologic Malignancies

Frontiers in Immunology, 2020
T cell cancer neoantigens are created from peptides derived from cancer-specific aberrant proteins, such as mutated and fusion proteins, presented in complex with human leukocyte antigens on the cancer cell surface. Because expression of the aberrant target protein is exclusive to malignant cells, immunotherapy directed against neoantigens should avoid
Melinda A. Biernacki, Melinda A. Biernacki, Marie Bleakley, Marie Bleakley   +3 more
openaire   +3 more sources

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Allergy and risk of hematologic malignancies: Associations and mechanisms

, 2014
Increasing evidence indicates that a dysregulated immune system, as the one found in allergic disorders, can affect survival of tumor cells. A possible association between allergies and risk of hematologic malignancies has been examined in several ...
Musolino, C., Minciullo, P.L., A. Allegra, P.L. Minciullo, S. Gangemi, Allegra, A., C. Musolino, Gangemi, S.   +7 more
core   +1 more source

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

Molecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge, Morten Tulstrup, Gabriele Todisco, Pedro Moura, Christophe Côme, Jakob Werner Hansen, Jakob Schmidt Jespersen, Balthasar Schlotmann, Maria Creignou, Mette Dahl, Claudia Schöllkopf, Klas Raaschou‐Jensen, Krister Wennerberg, Bo Porse, Joachim Weischenfeldt, Eva Hellström‐Lindberg, Lasse Sommer Kristensen, Kirsten Grønbæk   +17 more
wiley   +1 more source

Epidemiology of hematological malignancies

Annals of Oncology, 2007
Hematological malignancies comprise a collection of heterogeneous conditions, all originating from cells of the bone marrow and the lymphatic system. There are three major groups: leukemia, lymphoma, and plasma cell neoplasms. In general, in Western countries the overall incidence of hematological malignancies appears to be rising but it is very ...
D, Rodriguez-Abreu, A, Bordoni, E, Zucca
openaire   +2 more sources

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

Molecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano, Giuseppina Minopoli, Simona Romano, Laura Marrone, Katia Aquilano, Maria Lina Tornesello, Raffaella Faraonio   +6 more
wiley   +1 more source

Galectins in hematological malignancies

Current Opinion in Hematology, 2013
Galectins are a family of lectin molecules that have emerged as key players in inflammation and tumor progresssion by displaying intracellular and extracellular activities. This review describes the recent advances on the role of galectins in hematological neoplasms.Galectin-1 and galectin-3 are the best studied galectins in oncohematology.
Giordano, Mirta Nilda, Croci Russo, Diego Omar, Rabinovich, Gabriel Adrián   +2 more
openaire   +3 more sources